Want to see MGTX full AI Analyst Report?
Top Page
Meiragtx Holdings
(NASDAQ:MGTX)
Select Model
Select Model
Rating:67Neutral
Price Target:
$14.50
▼(-0.41% Downside)
Action:Reiterated
Date:08/17/26
The score is driven primarily by improved financial performance with a major TTM profitability and revenue inflection, tempered by historically high volatility and weak/uneven cash-flow conversion. Technicals add support due to a clear uptrend and positive momentum. Valuation is reasonable (P/E ~17.8) but lacks dividend support, while recent financing/debt restructuring is a constructive balance-sheet catalyst.
Positive Factors
Revenue inflection
The sharp TTM revenue increase indicates substantially expanded commercial activity and product-related monetization. If supported by recurring collaborations, licensing and manufacturing demand, this can materially improve the company’s operating scale over the next several quarters.
Negative Factors
Weak cash conversion
Positive earnings have not yet translated into comparably strong cash generation. Historical operating and free cash flow were deeply negative from 2021 through 2025, so the company may remain dependent on financing while the new profit profile matures.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue inflection
The sharp TTM revenue increase indicates substantially expanded commercial activity and product-related monetization. If supported by recurring collaborations, licensing and manufacturing demand, this can materially improve the company’s operating scale over the next several quarters.
Read all positive factors
Meiragtx Holdings (MGTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.43B
Dividend YieldN/A
Average Volume (3M)1.06M
Price to Earnings (P/E)19.2
Beta (1Y)1.69
Revenue Growth948.35%
EPS GrowthN/A
CountryUS
Employees403
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.76
Shares Outstanding96,043,000
10 Day Avg. Volume681,602
30 Day Avg. Volume1,056,260
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)-110.38
Price to Sales (P/S)7.86
P/FCF Ratio-12.74
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$23.20Price Target Upside59.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.13
Revenue Forecast (FY)$258.46M
Meiragtx Holdings Business Overview & Revenue Model
Company Description
MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular...
Meiragtx Holdings Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
64
Positive
Cash Flow
46
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 397.50M | 81.39M | 33.28M | 14.02M | 15.92M | 37.70M |
| Gross Profit | 386.34M | 76.55M | 9.49M | 14.02M | 15.92M | 37.70M |
| EBITDA | 259.87M | -89.40M | -121.69M | -57.05M | -116.07M | -71.40M |
| Net Income | 78.98M | -114.20M | -147.79M | -84.03M | -129.62M | -79.56M |
Balance Sheet | ||||||
| Total Assets | 396.45M | 244.43M | 269.75M | 326.74M | 318.24M | 320.16M |
| Cash, Cash Equivalents and Short-Term Investments | 143.17M | 65.93M | 103.66M | 129.57M | 115.52M | 137.70M |
| Total Debt | 112.32M | 88.69M | 84.80M | 89.26M | 92.25M | 23.73M |
| Total Liabilities | 180.67M | 250.22M | 201.92M | 188.57M | 200.50M | 134.76M |
| Stockholders Equity | 215.57M | -5.79M | 67.83M | 138.18M | 117.74M | 185.40M |
Cash Flow | ||||||
| Free Cash Flow | 6.31M | -50.19M | -109.45M | -125.54M | -118.06M | -65.75M |
| Operating Cash Flow | 13.69M | -46.36M | -104.50M | -105.36M | -73.10M | -10.53M |
| Investing Cash Flow | -27.53M | -4.11M | 23.48M | 34.03M | -44.96M | -61.72M |
| Financing Cash Flow | 128.89M | 12.27M | 54.53M | 84.02M | 95.20M | 1.71M |
Meiragtx Holdings Technical Analysis
Positive
14.56
Price Trends
12.78
Positive
11.21
Positive
9.52
Positive
Market Momentum
0.67
Negative
63.38
Neutral
84.23
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MGTX, the sentiment is Positive. The current price of 14.56 is above the 20-day moving average (MA) of 13.37, above the 50-day MA of 12.78, and above the 200-day MA of 9.52, indicating a bullish trend. The MACD of 0.67 indicates Negative momentum. The RSI at 63.38 is Neutral, neither overbought nor oversold. The STOCH value of 84.23 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for MGTX.
Meiragtx Holdings Risk Analysis
Meiragtx Holdings disclosed 78 risk factors in its most recent earnings report. Meiragtx Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Meiragtx Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $1.43B | 19.16 | 284.38% | ― | 948.35% | ― | |
61 Neutral | $2.02B | -14.25 | -56.19% | ― | -32.27% | -21.09% | |
56 Neutral | $868.44M | -5.72 | -41.33% | ― | 278712.12% | 26.59% | |
54 Neutral | $6.21B | -20.16 | -80.43% | ― | ― | -110.63% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
MGTX
Meiragtx Holdings
14.56
7.07
94.39%
TSHA
Taysha Gene Therapies
6.02
3.19
112.72%
FDMT
4D Molecular Therapeutics
15.56
9.38
151.78%
ERAS
Erasca
19.15
17.58
1119.75%
Meiragtx Holdings Corporate Events
Business Operations and StrategyPrivate Placements and Financing
MeiraGTx Secures Major Royalty Financing and Restructures Debt
Positive
Jul 7, 2026
On June 30, 2026, MeiraGTx entered into a Royalty Note Purchase Agreement with Oberland Capital affiliates providing up to $375 million in senior secured royalty financing tied to future net sales of three gene therapy products. An initial $100 mi...
Executive/Board ChangesShareholder Meetings
MeiraGTx Shareholders Back Board Slate and Auditor Renewal
Positive
Jun 15, 2026
On June 11, 2026, MeiraGTx Holdings plc held its annual general meeting of shareholders, with about 81.4% of outstanding ordinary shares represented. Shareholders elected three Class II directors, Ellen Hukkelhoven, Ph.D., Nicole Seligman, and Deb...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.